S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.27 (+2.51%)
MSFT   332.17 (-1.32%)
FB   327.78 (-3.03%)
GOOGL   2,855.15 (-1.91%)
AMZN   3,513.63 (-1.35%)
TSLA   1,136.76 (-0.02%)
NVDA   325.29 (-2.54%)
BABA   127.18 (-3.37%)
NIO   39.21 (-3.09%)
CGC   10.50 (-5.06%)
AMD   158.29 (-2.24%)
GE   95.48 (-2.97%)
MU   85.23 (-1.06%)
T   22.73 (-4.86%)
F   19.25 (-2.14%)
DIS   144.40 (-2.31%)
ACB   6.27 (-2.64%)
AMC   34.23 (-7.08%)
PFE   54.17 (+3.38%)
BA   195.95 (-1.28%)
S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.27 (+2.51%)
MSFT   332.17 (-1.32%)
FB   327.78 (-3.03%)
GOOGL   2,855.15 (-1.91%)
AMZN   3,513.63 (-1.35%)
TSLA   1,136.76 (-0.02%)
NVDA   325.29 (-2.54%)
BABA   127.18 (-3.37%)
NIO   39.21 (-3.09%)
CGC   10.50 (-5.06%)
AMD   158.29 (-2.24%)
GE   95.48 (-2.97%)
MU   85.23 (-1.06%)
T   22.73 (-4.86%)
F   19.25 (-2.14%)
DIS   144.40 (-2.31%)
ACB   6.27 (-2.64%)
AMC   34.23 (-7.08%)
PFE   54.17 (+3.38%)
BA   195.95 (-1.28%)
S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.27 (+2.51%)
MSFT   332.17 (-1.32%)
FB   327.78 (-3.03%)
GOOGL   2,855.15 (-1.91%)
AMZN   3,513.63 (-1.35%)
TSLA   1,136.76 (-0.02%)
NVDA   325.29 (-2.54%)
BABA   127.18 (-3.37%)
NIO   39.21 (-3.09%)
CGC   10.50 (-5.06%)
AMD   158.29 (-2.24%)
GE   95.48 (-2.97%)
MU   85.23 (-1.06%)
T   22.73 (-4.86%)
F   19.25 (-2.14%)
DIS   144.40 (-2.31%)
ACB   6.27 (-2.64%)
AMC   34.23 (-7.08%)
PFE   54.17 (+3.38%)
BA   195.95 (-1.28%)
S&P 500   4,595.04 (-1.29%)
DOW   34,656.96 (-1.36%)
QQQ   395.00 (-1.17%)
AAPL   164.27 (+2.51%)
MSFT   332.17 (-1.32%)
FB   327.78 (-3.03%)
GOOGL   2,855.15 (-1.91%)
AMZN   3,513.63 (-1.35%)
TSLA   1,136.76 (-0.02%)
NVDA   325.29 (-2.54%)
BABA   127.18 (-3.37%)
NIO   39.21 (-3.09%)
CGC   10.50 (-5.06%)
AMD   158.29 (-2.24%)
GE   95.48 (-2.97%)
MU   85.23 (-1.06%)
T   22.73 (-4.86%)
F   19.25 (-2.14%)
DIS   144.40 (-2.31%)
ACB   6.27 (-2.64%)
AMC   34.23 (-7.08%)
PFE   54.17 (+3.38%)
BA   195.95 (-1.28%)
NASDAQ:QLGN

Qualigen Therapeutics Stock Competitors

$1.47
-0.11 (-6.96%)
(As of 11/30/2021 02:10 PM ET)
Add
Compare
Today's Range
$1.34
$1.65
50-Day Range
$0.94
$2.56
52-Week Range
$0.93
$4.66
Volume
228,822 shs
Average Volume
2.47 million shs
Market Capitalization
$42.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.6

Qualigen Therapeutics (NASDAQ:QLGN) Vs. OBSV, TERN, NXTC, VIRX, MNOV, RPHM, LRMR, MIST, ANEB, and BCTX

Should you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include ObsEva (OBSV), Terns Pharmaceuticals (TERN), NextCure (NXTC), Viracta Therapeutics (VIRX), MediciNova (MNOV), Reneo Pharmaceuticals (RPHM), Larimar Therapeutics (LRMR), Milestone Pharmaceuticals (MIST), Anebulo Pharmaceuticals (ANEB), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical preparations" industry.

Qualigen Therapeutics vs.

Qualigen Therapeutics (NASDAQ:QLGN) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$1.67 millionN/AN/A
Terns PharmaceuticalsN/AN/A-$40.05 millionN/AN/A

Terns Pharmaceuticals' return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen Therapeutics N/A -160.68% -63.79%
Terns Pharmaceuticals N/A N/A N/A

8.7% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Terns Pharmaceuticals shares are owned by institutional investors. 4.7% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Terns Pharmaceuticals received 8 more outperform votes than Qualigen Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Qualigen Therapeutics an outperform vote while only 66.67% of users gave Terns Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Qualigen TherapeuticsOutperform Votes
6
100.00%
Underperform Votes
No Votes
Terns PharmaceuticalsOutperform Votes
14
66.67%
Underperform Votes
7
33.33%

Qualigen Therapeutics currently has a consensus target price of $6.50, indicating a potential upside of 354.55%. Terns Pharmaceuticals has a consensus target price of $26.50, indicating a potential upside of 295.52%. Given Qualigen Therapeutics' higher probable upside, equities research analysts plainly believe Qualigen Therapeutics is more favorable than Terns Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Terns Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Terns Pharmaceuticals. Qualigen Therapeutics' average media sentiment score of 0.42 beat Terns Pharmaceuticals' score of 0.00 indicating that Qualigen Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Terns Pharmaceuticals Neutral

Summary

Qualigen Therapeutics beats Terns Pharmaceuticals on 6 of the 11 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Qualigen Therapeutics (NASDAQ:QLGN) vs. Its Competitors

TypeQualigen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$42.80M$5.83B$4.94B$7.86B
Dividend YieldN/A2.59%2.04%2.48%
P/E RatioN/A10.3919.3921.34
Price / SalesN/A568.592,542.81281.32
Price / CashN/A25.0141.41137.68
Price / Book-1.3010.879.5410.62
Net Income-$1.67M$95.45M$95.31M$153.87M
7 Day Performance-42.58%-2.73%111.29%-3.20%
1 Month Performance27.83%-9.81%106.84%-6.44%
1 Year Performance-57.76%15.97%161.16%29.76%

Qualigen Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBSV
ObsEva
1.6781 of 5 stars
$2.18
-2.3%
$14.33
-557.5%
+8.8%$169.98M$20K-2.5645Analyst Report
Short Interest ↑
TERN
Terns Pharmaceuticals
1.9131 of 5 stars
$6.70
-3.1%
$26.50
-295.5%
N/A$169.29MN/A0.0030
NXTC
NextCure
1.9686 of 5 stars
$6.12
-2.1%
$16.67
-172.3%
-42.3%$169.07M$22.38M-2.4990
VIRX
Viracta Therapeutics
2.0333 of 5 stars
$4.43
-3.2%
$32.67
-637.4%
N/A$165.29M$120K0.008News Coverage
Gap Down
MNOV
MediciNova
1.9248 of 5 stars
$3.33
-2.7%
$15.00
-350.5%
-42.7%$163.30MN/A-14.489
RPHM
Reneo Pharmaceuticals
2.1583 of 5 stars
$6.68
-4.9%
$34.75
-420.2%
N/A$163.15MN/A0.0018
LRMR
Larimar Therapeutics
1.4731 of 5 stars
$9.04
-2.0%
$29.50
-226.3%
-59.2%$160.10MN/A-2.6928
MIST
Milestone Pharmaceuticals
1.9398 of 5 stars
$5.35
-4.7%
$20.00
-273.8%
-14.9%$159.70MN/A-6.2928
ANEB
Anebulo Pharmaceuticals
2.0333 of 5 stars
$6.66
-5.9%
$15.00
-125.2%
N/A$155.44MN/A0.002Gap Up
BCTX
BriaCell Therapeutics
0.1667 of 5 stars
$10.07
-0.9%
N/AN/A$154.78MN/A-11.99147,000Positive News
APTX
Aptinyx
2.3331 of 5 stars
$2.27
-2.6%
$8.00
-252.4%
-38.8%$153.72M$1.56M-2.2334Short Interest ↓
CRVS
Corvus Pharmaceuticals
2.5048 of 5 stars
$3.30
-4.5%
$4.83
-46.5%
-14.4%$153.62MN/A55.0042Short Interest ↓
Positive News
SLGL
Sol-Gel Technologies
1.7115 of 5 stars
$7.53
-8.1%
$19.00
-152.3%
-16.3%$153.54M$8.77M-8.9665Gap Up
GALT
Galectin Therapeutics
2.2998 of 5 stars
$2.58
-3.5%
$14.00
-442.6%
-6.0%$153.10MN/A-4.786
EQ
Equillium
2.2 of 5 stars
$5.18
-0.6%
$14.50
-179.9%
+4.7%$152.24MN/A-3.8431
STSA
Satsuma Pharmaceuticals
2.6281 of 5 stars
$4.74
-3.2%
$10.38
-118.9%
+4.5%$149.45MN/A-2.3719Positive News
Gap Down
BIVI
BioVie
2.0333 of 5 stars
$5.96
-10.7%
$50.00
-738.9%
-25.3%$148.76MN/A0.003Analyst Report
News Coverage
ONCT
Oncternal Therapeutics
1.6331 of 5 stars
$2.94
-0.3%
$15.20
-417.0%
+10.5%$145.32M$3.38M-5.2513
ZYNE
Zynerba Pharmaceuticals
1.6331 of 5 stars
$3.44
-2.3%
$10.56
-207.0%
-23.6%$141.79M$90K-3.1626
ONCR
Oncorus
2.6583 of 5 stars
$5.47
-0.5%
$35.00
-539.9%
-78.1%$141.18MN/A-2.3456
NCNA
NuCana
1.7731 of 5 stars
$2.69
-3.7%
$9.00
-234.6%
-38.0%$140.32MN/A-2.382,020
VBLT
Vascular Biogenics
1.6781 of 5 stars
$2.24
-3.6%
$5.75
-156.7%
+82.7%$139.70M$920K-4.3938
BCEL
Atreca
2.3831 of 5 stars
$3.75
-5.3%
$24.50
-553.3%
-74.9%$139.31MN/A-1.34130
DARE
Daré Bioscience
1.8114 of 5 stars
$1.79
-2.0%
$8.00
-348.2%
+29.6%$136.73MN/A-2.4120Short Interest ↓
XERS
Xeris Pharmaceuticals
2.2314 of 5 stars
$2.02
-1.0%
$6.42
-217.7%
-55.0%$134.32M$20.16M-1.34180Gap Up
KZIA
Kazia Therapeutics
1.5715 of 5 stars
$10.15
-1.5%
$17.50
-72.4%
-1.8%$133.98M$11.35M0.002,021News Coverage
Positive News
RDHL
RedHill Biopharma
1.8114 of 5 stars
$2.86
-2.1%
$18.75
-555.6%
-68.4%$133.47M$64.36M-1.22182News Coverage
Gap Up
CFRX
ContraFect
1.9414 of 5 stars
$3.39
-5.0%
$11.75
-246.6%
-49.7%$133.33MN/A-4.9933Gap Up
Trading Halted
CLVR
Clever Leaves
1.8667 of 5 stars
$4.81
-1.5%
$9.00
-87.1%
N/A$129.49M$12.12M0.00477
PBYI
Puma Biotechnology
2.2964 of 5 stars
$3.16
-2.5%
$10.00
-216.5%
-73.7%$129.20M$225.10M-2.63267Negative News
Gap Down
ENLV
Enlivex Therapeutics
1.7 of 5 stars
$6.91
-4.6%
$33.00
-377.6%
-16.1%$126.52MN/A-7.0550News Coverage
Positive News
KALA
Kala Pharmaceuticals
2.3648 of 5 stars
$1.93
-4.1%
$7.50
-288.6%
-74.7%$126.42M$6.36M-0.95188
SVRA
Savara
2.3714 of 5 stars
$1.09
-5.1%
$4.67
-330.1%
-14.3%$123.55M$260K0.00N/A
TYME
Tyme Technologies
1.3798 of 5 stars
$0.72
-2.3%
N/A-27.5%$123.28MN/A-4.4718News Coverage
IMV
IMV
1.2265 of 5 stars
$1.50
-3.3%
$3.10
-106.3%
-56.8%$123.21M$220K-3.3377
ETTX
Entasis Therapeutics
1.8981 of 5 stars
$2.57
-0.4%
$6.50
-152.9%
+46.6%$122.44M$7M-2.6847Short Interest ↑
MREO
Mereo BioPharma Group
1.5798 of 5 stars
$1.80
-0.6%
$10.00
-455.6%
-25.7%$122.02MN/A0.002,020Short Interest ↑
News Coverage
Gap Up
BLRX
BioLineRx
1.825 of 5 stars
$2.57
-0.0%
$14.50
-464.2%
+10.8%$121.97MN/A-2.042,020Short Interest ↑
TLSA
Tiziana Life Sciences
1.5531 of 5 stars
$1.24
-0.8%
$8.00
-545.2%
-51.9%$120.66MN/A0.0011Short Interest ↓
Positive News
Gap Down
SCPH
scPharmaceuticals
1.7131 of 5 stars
$4.36
-4.1%
$10.33
-137.0%
-50.1%$119.27MN/A-4.1927Gap Down
ADMP
Adamis Pharmaceuticals
1.1114 of 5 stars
$0.80
-2.4%
N/A+77.3%$118.96M$16.53M0.00130
GMTX
Gemini Therapeutics
2.1583 of 5 stars
$2.74
-0.7%
$19.25
-602.6%
N/A$118.12MN/A0.0029Analyst Downgrade
CNCE
Concert Pharmaceuticals
2.0914 of 5 stars
$3.39
-1.2%
$16.60
-389.7%
-69.8%$117.50M$7.90M-1.7171Short Interest ↑
SIOX
Sio Gene Therapies
1.7581 of 5 stars
$1.58
-0.6%
$7.75
-390.5%
-36.9%$115.25MN/A0.0038Short Interest ↓
OTIC
Otonomy
2.0648 of 5 stars
$2.02
-0.0%
$5.75
-184.7%
-55.1%$114.50M$270K-2.4956
HTBX
Heat Biologics
1.825 of 5 stars
$4.43
-1.8%
$19.25
-334.5%
-45.5%$112.52M$2.95M0.0039Positive News
Gap Up
TRVN
Trevena
1.65 of 5 stars
$0.68
-2.3%
$6.00
-779.2%
-72.8%$112.27M$3.07M-2.5325Gap Down
ORPH
Orphazyme A/S
1.3782 of 5 stars
$3.21
-0.6%
$5.00
-55.8%
-67.2%$112.20MN/A0.00141Short Interest ↑
QLI
Qilian International Holding Group
1 of 5 stars
$3.11
-0.3%
N/AN/A$111.18M$50.03M0.00292Short Interest ↑
News Coverage
BFRA
Biofrontera
0.8798 of 5 stars
$3.91
-9.5%
N/A-40.3%$110.89M$36.19M-5.36138Earnings Report
Short Interest ↑
News Coverage
This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.